靶向磷脂酰肌醇-3-激酶抗肿瘤转移的研究进展  

Research Progress on Drugs Targeting PI3K in Anti-tumor Metastasis

作　　者：王营营 党丽娟 赵文楠[1] 李慧颖 王廷涛[2] 孔德新[1] WANG Ying-ying;DANG Li-juan;ZHAO Wen-nan;LI Hui-ying;WANG Ting-tao;KONG De-xin(College of Pharmaceutical Sciences,Tianjin Medical University,Tianjin 300070,China;Maternity Department,Affiliated Hospital of Jining Medical University,Jining 272000,China)

机构地区：[1]天津医科大学药学院,天津300070 [2]济宁医学院附属医院妇科,山东济宁272000

出　　处：《食品与药品》2024年第1期88-95,共8页Food and Drug

摘　　要：肿瘤转移是肿瘤死亡的首要原因,约占肿瘤死亡的90%。目前临床上对肿瘤转移的治疗方法有限且收效甚微。磷脂酰肌醇-3-激酶(PI3K)信号转导是细胞内最重要的通路之一,在肿瘤的发生、发展及转移中发挥至关重要的作用。因此PI3K抑制剂的研发得到国内外众多药企的广泛关注,目前已有5种PI3K抑制剂被批准上市,更多的抑制剂正在进行临床研究。迄今为止的临床试验结果表明PI3K抑制剂单独用药的抗肿瘤疗效并不理想,因此与其他药物的联合用药受到研究人员和临床医生的关注。本文概述了PI3K信号通路及其在肿瘤转移各个过程中的作用,总结了PI3K抑制剂单独及与其他药物联用抗肿瘤转移的研究进展,为PI3K抑制剂的进一步开发和应用提供参考。Tumor metastasis is the primary cause of cancer lethality,accounting for approximately 90%of cancer-related deaths.The current clinical treatment methods for tumor metastasis are limited.Phosphatidylinositol-3-kinase(PI3K)signaling is one of the most important pathways in cells and plays a vital role in the occurrence,development and metastasis of tumors.Therefore,many pharmaceutical companies focus on development of PI3K inhibitors.Until now,five PI3K inhibitors have been approved by Food and Drug Administration(FDA)of USA,and more inhibitors are being studied in clinical trials.Many clinical trial results showed limited efficacy of PI3K inhibitors administered alone,therefore the combinations with other antitumor drugs are being tested.This article summarizes the PI3K signaling pathway and its role in the processes of tumor metastasis and also sorts out the new developments in the application of PI3K inhibitors alone or in combination with other drugs in tumor metastasis.It will provide a powerful reference for the further development and application of PI3K inhibitors.

关 键 词：肿瘤转移 磷脂酰肌醇-3-激酶 抑制剂 

分 类 号：R730.5[医药卫生—肿瘤]